Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA.
Neurobiol Dis. 2010 Sep;39(3):311-7. doi: 10.1016/j.nbd.2010.04.015. Epub 2010 May 6.
The c-Jun N-terminal kinase (JNK) pathway potentially links together the three major pathological hallmarks of Alzheimer's disease (AD): development of amyloid plaques, neurofibrillary tangles, and brain atrophy. As activation of the JNK pathway has been observed in amyloid models of AD in association with peri-plaque regions and neuritic dystrophy, as we confirm here for Tg2576/PS(M146L) transgenic mice, we directly tested whether JNK inhibition could provide neuroprotection in a novel brain slice model for amyloid precursor protein (APP)-induced neurodegeneration. We found that APP/amyloid beta (Abeta)-induced neurodegeneration is blocked by both small molecule and peptide inhibitors of JNK, and provide evidence that this neuroprotection occurs downstream of APP/Abeta production and processing. Our findings demonstrate that Abeta can induce neurodegeneration, at least in part, through the JNK pathway and suggest that inhibition of JNK may be of therapeutic utility in the treatment of AD.
c-Jun N-末端激酶(JNK)通路可能将阿尔茨海默病(AD)的三个主要病理标志联系在一起:淀粉样斑块的形成、神经原纤维缠结和脑萎缩。由于 JNK 通路的激活已在 AD 的淀粉样模型中与斑块周围区域和神经纤维变性相关联,正如我们在此为 Tg2576/PS(M146L)转基因小鼠所证实的那样,我们直接测试了 JNK 抑制是否可以在 APP 诱导的神经退行性变的新型脑切片模型中提供神经保护作用。我们发现,小分子和 JNK 肽抑制剂均可阻断 APP/β-淀粉样蛋白(Abeta)诱导的神经退行性变,并提供证据表明这种神经保护作用发生在 APP/Abeta 产生和处理的下游。我们的研究结果表明,Abeta 至少部分通过 JNK 通路诱导神经退行性变,并表明 JNK 抑制可能在 AD 的治疗中有治疗作用。